Tyme Technologies (TYME) Stock Forecast, Price & News

Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions

Are investors shorting Tyme Technologies?

Tyme Technologies saw a drop in short interest in April. As of April 30th, there was short interest totaling 1,390,000 shares, a drop of 34.4% from the April 15th total of 2,120,000 shares. Based on an average daily trading volume, of 638,600 shares, the short-interest ratio is presently 2.2 days. Approximately 1.2% of the shares of the company are sold short.
View Tyme Technologies' Short Interest.

When is Tyme Technologies' next earnings date?

Tyme Technologies is scheduled to release its next quarterly earnings announcement on Thursday, June 9th 2022.
View our earnings forecast for Tyme Technologies.

How were Tyme Technologies' earnings last quarter?

Tyme Technologies, Inc. (NASDAQ:TYME) announced its earnings results on Monday, November, 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.03.
View Tyme Technologies' earnings history.

Who are Tyme Technologies' key executives?

Tyme Technologies' management team includes the following people:

• Mr. Richard Cunningham, CEO & Director (Age 51, Pay $355.97k)
• Mr. Steven E. Hoffman, Co-Founder & Director (Age 59, Pay $819.66k) (LinkedIn Profile)
• Mr. James Biehl J.D., Chief Legal Officer & Sec. (Age 58, Pay $645.52k)
• Dr. Jonathan M. Eckard, Chief Bus. Officer (Age 48, Pay $556.56k)
• Mr. Frank L. Porfido, Chief Financial Officer (Age 58)
• Dr. Jan Marie-Albert Van Tornout M.D., M.Sc., Acting Chief Medical Officer (Age 66)

Who are some of Tyme Technologies' key competitors?

Some companies that are related to Tyme Technologies include Athersys (ATHX), Immunic (IMUX), Longeveron (LGVN), Pliant Therapeutics (PLRX), Concert Pharmaceuticals (CNCE), Viking Therapeutics (VKTX), Oramed Pharmaceuticals (ORMP), Vaccitech (VACC), XBiotech (XBIT), Verrica Pharmaceuticals (VRCA), LumiraDx (LMDX), OptiNose (OPTN), KemPharm (KMPH), Allakos (ALLK) and CymaBay Therapeutics (CBAY).
View all of TYME's competitors.

What other stocks do shareholders of Tyme Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Vaxart (VXRT), Allena Pharmaceuticals (ALNA), OpGen (OPGN), Selecta Biosciences (SELB), MEI Pharma (MEIP), Pfizer (PFE) and SCYNEXIS (SCYX).

What is Tyme Technologies' stock symbol?

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

Who are Tyme Technologies' major shareholders?

Tyme Technologies' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.25%), Renaissance Technologies LLC (0.73%), GSA Capital Partners LLP (0.34%), Kercheville Advisors LLC (0.06%), Group One Trading L.P. (0.00%) and Simplex Trading LLC (0.00%). Company insiders that own Tyme Technologies stock include Barbara Galaini, David Carberry, Diana F Cantor, Douglas A Michels, James Biehl, Michael Demurjian, Steve Hoffman, Tornout Jan M Van and Tornout Jan M Van.
View institutional ownership trends for Tyme Technologies.

Which major investors are selling Tyme Technologies stock?

TYME stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Kercheville Advisors LLC, Simplex Trading LLC, HAP Trading LLC, and Cutler Group LP. Company insiders that have sold Tyme Technologies company stock in the last year include Diana F Cantor, Michael Demurjian, and Steve Hoffman.
View insider buying and selling activity for Tyme Technologies or view top insider-selling stocks.

Which major investors are buying Tyme Technologies stock?

TYME stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, GSA Capital Partners LLP, and Group One Trading L.P.. Company insiders that have bought Tyme Technologies stock in the last two years include Barbara Galaini, David Carberry, Douglas A Michels, James Biehl, Michael Demurjian, and Tornout Jan M Van.
View insider buying and selling activity for Tyme Technologies or or view top insider-buying stocks.

How do I buy shares of Tyme Technologies?

Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tyme Technologies' stock price today?

One share of TYME stock can currently be purchased for approximately $0.26.

How much money does Tyme Technologies make?

Tyme Technologies has a market capitalization of $45.62 million. The company earns $-28.98 million in net income (profit) each year or ($0.140010) on an earnings per share basis.

How many employees does Tyme Technologies have?

Tyme Technologies employs 17 workers across the globe.

What is Tyme Technologies' official website?

The official website for Tyme Technologies is www.tymeinc.com.

How can I contact Tyme Technologies?

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at (212) 461-2315 or via email at [email protected].